Skip to main content

Table 1 (abstract P079) Effect of caplacizumab on RICO activity in the healthy volunteer study

From: 41st International Symposium on Intensive Care and Emergency Medicine

 

10 mg IV

10 mg IV

10 mg SC

10 mg SC

Analysis time point at Day 1, n (%)

White (n = 8)

Japanese (n = 8)

White (n = 8)

Japanese (n = 8)

1 hour post-dose: RICO < 20% / RICO ≥20%

7 (87.5) / 1 (12.5)

8 (100.0) / 0

4 (50.0) / 4 (50.0)

4 (50.0) / 4 (50.0)

3 hours post-dose: RICO < 20% / RICO ≥20%

8 (100.0) / 0

8 (100.0) / 0

8 (100.0) / 0

8 (100.0) / 0

24 hours post-dose: RICO < 20% / RICO ≥20%

6 (75.0) / 2 (25.0)

8 (100.0) / 0

8 (100.0) / 0

8 (100.0) / 0

48 hours post-dose: RICO < 20% / RICO ≥20%

1 (12.5) / 7 (87.5)

0 / 8 (100.0)

5 (62.5) / 3 (37.5)

6 (75.0) / 2 (25.0)

72 hours post-dose: RICO < 20% / RICO ≥20%

0 / 8 (100.0)

0 / 8 (100.0)

0 / 8 (100.0)

0 / 8 (100.0)

  1. IV, intravenous; RICO, ristocetin cofactor; SC, subcutaneous. RICO activity was ≥20% in all healthy volunteers at baseline